Produktbild: Cancer Immunotherapy

Cancer Immunotherapy

105,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

30.10.2024

Herausgeber

David B. Teplow

Verlag

Elsevier Science & Technology

Maße (B/H)

15,2/22,8 cm

Gewicht

590 g

Sprache

Englisch

ISBN

978-0-443-23534-4

Beschreibung

Portrait

David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid ?-protein (Alzheimer's disease) and ?-synuclein (Parkinson's disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

30.10.2024

Herausgeber

David B. Teplow

Verlag

Elsevier Science & Technology

Maße (B/H)

15,2/22,8 cm

Gewicht

590 g

Sprache

Englisch

ISBN

978-0-443-23534-4

EU-Ansprechpartner

Elsevier B.V.
Radarweg 29
1043 NX Amsterdam
NL
productsafety@elsevier.com

Herstelleradresse

Elsevier Science & Technology
London Wall 125
EC2Y 5AS London
GB
tradeorders@elsevier.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Die Leseprobe wird geladen.
  • Produktbild: Cancer Immunotherapy
  • 1. The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy
    Matt Giacalone
    2. TBA
    Tiziana Vavalà
    3. Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy
    Rio Sugimura and Logan Tang
    4. Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?
    Moein Ala, Fatemeh Afra, Seyed Parsa Eftekhar and Amir Salehi Farid
    5. Rational Design of adjuvants boosts cancer vaccines
    Xia Li, Mitsuhiro Ebara, Naoto Shirahata, Tomohiko Yamazaki and Nobutaka Hanagata
    6. Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma
    Khushwant S. Yadav
    7. MAGNETIC NANOPARTICLES: AN EMERGING NANOMEDICINE FOR CANCER IMMUNOTHERAPY
    Phoomipat Jungcharoen, Jutatip Panaampon, Thanit Imemkamon and Charupong Saengboonmee
    8. TBA
    Mi Liu
    9. TBA
    Sarbajit Mukherjee
    10. TBA
    Gerardo Cazzato III
    11. Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment
    Eric Jou